

Adverse Effects of Amiodarone

PACE - Pacing and Clinical Electrophysiology

21, 108-120

DOI: [10.1111/j.1540-8159.1998.tb01068.x](https://doi.org/10.1111/j.1540-8159.1998.tb01068.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Interactions between implantable cardioverter-defibrillators and class III agents. <i>American Journal of Cardiology</i> , 1998, 82, 411-481.	1.6	34
2	Effects of the I _{Kr} -blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study. <i>Cardiovascular Drugs and Therapy</i> , 1999, 13, 329-338.	2.6	8
3	Neurodevelopment After In Utero Amiodarone Exposure. <i>Neurotoxicology and Teratology</i> , 1999, 21, 261-265.	2.4	35
4	Clinical Potential of Emerging Antiarrhythmic Agents. <i>Drugs in R and D</i> , 1999, 1, 279-290.	2.2	2
5	Amiodarone as a First-Choice Drug for Restoring Sinus Rhythm in Patients With Atrial Fibrillation. <i>Chest</i> , 2000, 117, 1538-1545.	0.8	122
6	Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 244-253.	2.4	170
7	The Management of Atrial Fibrillation in the ICU. <i>Journal of Intensive Care Medicine</i> , 2000, 15, 181-190.	2.8	4
8	The Management of Atrial Fibrillation in the ICU. <i>Journal of Intensive Care Medicine</i> , 2000, 15, 181-190.	2.8	2
9	Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. <i>British Heart Journal</i> , 2000, 84, 251-257.	2.1	92
10	Practical Guidelines for Clinicians Who Treat Patients With Amiodarone. <i>Archives of Internal Medicine</i> , 2000, 160, 1741.	3.8	178
11	Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. <i>European Heart Journal Supplements</i> , 2001, 3, K70-K80.	0.1	168
12	First clinical experience with the rapid-, short-acting amiodarone derivative E 047/1 after cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2002, 19, 23.	1.7	0
13	Clinical Relevance and Management of Drug-Related QT Interval Prolongation. <i>Pharmacotherapy</i> , 2003, 23, 881-908.	2.6	88
14	Amiodarone versus placebo and class I drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2003, 41, 255-262.	2.8	138
15	Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 110-122.	4.7	57
16	Antiarrhythmic drug therapy of atrial fibrillation. <i>Cardiology Clinics</i> , 2004, 22, 21-34.	2.2	10
17	Case Report 2004. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2004, 18, 366-374.	1.3	2
18	Validated Spectrophotometric Methods for the Determination of Amiodarone Hydrochloride in Commercial Dosage Forms Using p-Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone. <i>Analytical Sciences</i> , 2004, 20, 1231-1235.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Flow injection chemiluminescent determination of amiodarone in pharmaceutical preparations using photogenerated tris(2,2'-bipyridyl)ruthenium(III). Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 143-147.	2.8	8
20	Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice?. Clinical Cardiology, 2006, 29, 97-102.	1.8	22
21	Prediction of Atrial Fibrillation via Atrial Electromechanical Interval After Coronary Artery Bypass Grafting. Circulation, 2007, 116, 2012-2017.	1.6	41
22	Efflux Transport of N-monodesethylamiodarone by the Human Intestinal Cell-Line Caco-2 Cells. Drug Metabolism and Pharmacokinetics, 2007, 22, 307-312.	2.2	11
23	A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007. Heart Rhythm, 2007, 4, 1250-1259.	0.7	220
24	Metoprolol Versus Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery. Annals of Internal Medicine, 2010, 153, 703.	3.9	33
25	Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence. Current Drug Safety, 2010, 5, 65-72.	0.6	21
26	QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opinion on Drug Safety, 2010, 9, 699-712.	2.4	23
27	Cardiac Ion Channels and Mechanisms for Protection Against Atrial Fibrillation. , 2011, 162, 1-58.		13
28	Physiologic Foundations of Cardiopulmonary Resuscitation. , 2011, , 449-473.		1
29	Comparison of Effectiveness and Safety of Ranolazine Versus Amiodarone for Preventing Atrial Fibrillation After Coronary Artery Bypass Grafting. American Journal of Cardiology, 2011, 108, 673-676.	1.6	102
30	Topical Application of a Biodegradable Disc With Amiodarone for Atrial Fibrillation. Annals of Thoracic Surgery, 2011, 91, 734-739.	1.3	17
31	Amiodarone-Induced Thrombosis. American Journal of Therapeutics, 2012, 19, 389-391.	0.9	3
32	Solubility of 2-Butyl-3-benzofuranyl 4-(2-(Diethylamino)ethoxy)-3,5-diiodophenyl Ketone Hydrochloride (Amiodarone HCl) in Ethanol + Water and N-Methyl-2-pyrrolidone + Water Mixtures at Various Temperatures. Journal of Chemical & Engineering Data, 2012, 57, 1544-1550.	1.9	70
33	Rapid Stimulating Effect of the Antiarrhythmic Agent Amiodarone on Absorption of Organic Anion Compounds. Drug Metabolism and Pharmacokinetics, 2013, 28, 178-186.	2.2	9
34	Anaphylaxis during intravenous administration of amiodarone. Annals of Cardiac Anaesthesia, 2013, 16, 229.	0.6	5
35	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. Cardiology Clinics, 2014, 32, 507-519.	2.2	3
36	Intrapericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation. Journal of Cardiac Surgery, 2016, 31, 253-258.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Diagnostic Evaluation and Follow-Up of Patients with Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 179-191.	2.1	1
38	Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. <i>American Journal of Medicine</i> , 2016, 129, 468-475.	1.5	86
39	Congenital Cardiac Intensive Care and Management of Cardiac Arrest. , 2017, , 953-979.		0
40	"Blue-grey syndrome" - A rare adverse effect of amiodarone. <i>Cor Et Vasa</i> , 2018, 60, e638-e644.	0.1	4
41	Efficacy and Safety of Low-Dose Amiodarone Therapy for Tachyarrhythmia in Congenital Heart Disease. <i>Pediatric Cardiology</i> , 2018, 39, 1016-1022.	1.3	11
43	Improvement in Dyssynchrony with Pharmacological Ablation of Right-Sided Accessory Pathway-Induced Cardiomyopathy in Infants. <i>International Heart Journal</i> , 2019, 60, 1201-1205.	1.0	4
44	Cardiovascular Collapse with Intravenous Amiodarone in Children: A Multi-Center Retrospective Cohort Study. <i>Pediatric Cardiology</i> , 2019, 40, 925-933.	1.3	14
45	Drug-induced pulmonary diseases. , 2020, , 393-408.		0
46	Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. <i>Heart Rhythm</i> , 2020, 17, 560-566.	0.7	11
47	Amiodarone-induced neuromyopathy in a geriatric patient. <i>BMJ Case Reports</i> , 2020, 13, e236620.	0.5	3
48	Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. <i>Frontiers in Pharmacology</i> , 2021, 12, 638445.	3.5	14
49	Optimal Management of Amiodarone Therapy: Efficacy and Side Effects. <i>Pharmacotherapy</i> , 1998, 18, .	2.6	2
50	Class III Antiarrhythmic Drugs: Amiodarone, Ibutilide, and Sotalol. , 2004, , 932-941.		11
51	Review of Common Adverse Effects of Selected Antiarrhythmic Drugs. <i>Critical Care Nursing Quarterly</i> , 2000, 22, 23-38.	0.8	10
52	A Review of Structure Activity Relationship of Amiodarone and Its Derivatives. <i>Open Journal of Medicinal Chemistry</i> , 2016, 06, 37-42.	0.7	1
53	First clinical experience with the rapid-, short-acting amiodarone derivative E 047/1 after cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2002, 19, 23-31.	1.7	0
54	Cardioversion of Recent Onset Atrial Fibrillation: Which Drug to Prefer in the Individual Patient?. , 2004, , 57-63.		0
56	The Place of Antiarrhythmic Drugs and Rhythm Control in the Treatment of Atrial Fibrillation. <i>European Cardiology Review</i> , 2009, 5, 36.	2.2	0

#	ARTICLE	IF	CITATIONS
58	Amiodarone induced pulmonary toxicity. <i>Vnitri Lekarstvi</i> , 2021, 67, E18-E23.	0.2	2
59	Sotalol versus amiodarone for postoperative junctional tachycardia after congenital heart surgery. <i>Heart Rhythm</i> , 2022, 19, 450-456.	0.7	4
60	Anaphylactic Shock as a Rare Side Effect of Intravenous Amiodarone. <i>Cureus</i> , 2022, 14, e21118.	0.5	1
61	Development and Validation of a Novel HPLC Method to Analyse Metabolic Reaction Products Catalysed by the CYP3A2 Isoform: In Vitro Inhibition of CYP3A2 Enzyme Activity by Aspirin (Drugs Often) Tj ETQq1 1.0.7843 14 rgBT /OV	1.0	1
62	An Overview of Systematic Reviews on the Effectiveness of Wenxin Keli in the Treatment of Atrial Fibrillation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-12.	1.2	0
63	Amiodarone and Thyroid Dysfunction. <i>Acta Clinica Croatica</i> , 2022, , .	0.2	2
64	Amiodarone-Induced Liver Attenuation on CT Scan: Alarming Signal for Toxicity and Prompt Discontinuation. <i>Cureus</i> , 2023, , .	0.5	1
66	Integrating distribution kinetics and toxicodynamics to assess repeat dose neurotoxicity in vitro using human BrainSpheres: a case study on amiodarone. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
67	Association between amiodarone use and risk of cataract: a population-based active-comparator study. <i>Postgraduate Medical Journal</i> , 0, , .	1.8	0